PAK1 Is a Novel Therapeutic Target in Tyrosine Kinase Inhibitor–Resistant Lung Adenocarcinoma Activated by the PI3K/AKT Signaling Regardless of EGFR Mutation

2016 ◽  
Vol 22 (21) ◽  
pp. 5370-5382 ◽  
Author(s):  
De-Wei Wu ◽  
Tzu-Chin Wu ◽  
Chih-Yi Chen ◽  
Huei Lee
Keyword(s):  
Tyrosine Kinase ◽  
Lung Adenocarcinoma ◽  
Tyrosine Kinase Inhibitor ◽  
Therapeutic Target ◽  
Egfr Mutation ◽  
Kinase Inhibitor ◽  
Akt Signaling ◽  
Novel Therapeutic

scholarly journals Direct activation of PP2A for the treatment of tyrosine kinase inhibitor–resistant lung adenocarcinoma

JCI Insight ◽  
2019 ◽  
Vol 4 (4) ◽  
Author(s):  
Rita Tohmé ◽  
Sudeh Izadmehr ◽  
Sai Gandhe ◽  
Giancarlo Tabaro ◽  
Sanjay Vallabhaneni ◽  
...  
Keyword(s):  
Tyrosine Kinase ◽  
Lung Adenocarcinoma ◽  
Tyrosine Kinase Inhibitor ◽  
Kinase Inhibitor ◽  
Direct Activation
Sign in / Sign up

Export Citation Format

Share Document